News

Lymphoseek (technetium Tc 99m tilmanocept) is now indicated for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with

The research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the

The acquisition is part of an ongoing collaboration and option agreement signed by the two companies in November 2012. As part of the acquisition, MorphoSys now has lanthipeptide

As announced on 2 October, 2014 Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity

The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah

The newly issued patents expand the already large intellectual property estate surrounding BMP-7, which include over 450 issues and pending patents, and extends important intellectual property in OA

The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness. Dr. Nicholas

Jean-Philippe Langevin, M.D., an expert in neurotrauma and a neurosurgeon at the Veterans Affairs Greater Los Angeles (VAGLA) medical center, will lead the study as Principal Investigator. The

The company also announced the establishment of its corporate headquarters in Cambridge, Massachusetts, where Patrick Anquetil, Ph.D., MBA and Mark Philip, Ph.D., MBA serve as chief executive officer